Medulloblastoma

CGCI developed the Medulloblastoma Project to apply newly emerging genomic methods towards the discovery of novel genetic alterations in medulloblastoma (MB)Opens in a New Tab. MB is the most common malignant brain tumor in children, accounting for approximately 20% of all pediatric brain tumors. Despite significant progress in treatment over the last several decades, about 50% of MB patients do not live more than 5 years after diagnosis. Moreover, current treatment of the disease is very aggressive, oftentimes causing serious long-term neurological side effects. To improve survival and quality-of-life of MB patients, new therapeutic strategies must be developed. 

CGCI investigators examined a number of MB tumors using high-density microarrays and Sanger sequencing. Their bioinformatics analysis uncovered several frequently altered genes not previously identified in MB, many of which have significant biological implications. Further analysis revealed the alteration profiles between pediatric and adult tumors are different, suggesting the initiation and progression of pediatric and adult cancers is likewise different. The completion of this project opens new doors for research and is an initial step towards finding improved therapeutic strategies for patients suffering from medulloblastoma.

The MB Project has completed all phases of the timeline.

CGCI Project Timeline: Phases 1 through 4

Visit the CGCI Overview page to learn more about the general timeline of CGCI projects.

Last updated: April 24, 2015